Since the introduction of BCG as the standard of care for the adjuvant therapy of NMIBC, there has been minimal progress in the development of new agents for this condition. In 2018, the FDA published guidance for drug development for NMIBC, based largely on cumulative advancements in the understanding of the clinical course of this disease, and on discussions with experts in the field (click here for link). Our early clinical development program has been carried out in accordance with these recommendations. The aim has been to demonstrate that inodiftagene has objective activity against established bladder cancer as a foundation for designing registrational trials.
Overall we have conducted six clinical trials in several cancer types, and administered inodiftagene in a compassionate use setting. The clinical trial program is listed below. It includes one clinical study in ovarian cancer, and two trials in unresectable pancreatic cancer. Inodiftagene has demonstrated anti-cancer activity against all these cancers. At this time, the company is focusing on the development of inodiftagene in NMIBC.
We have undertaken three clinical trials to date in bladder cancer. The first, a phase 1/2 dose-escalation trial, and the second, a phase 2 study utilized inodiftagene as monotherapy. The third trial was a phase 2 trial of inodiftagene administered as induction therapy in combination with BCG. The major findings of the trials are summarized here:
The FDA is clear in its guidance that it expects the demonstration of activity against active tumors. In our phase 1/2 and phase 2 trials, we employed a marker lesion design. Patients underwent complete resection of all existing tumors except a single marker tumor. After 12 weeks of BC-819 administration the response of the tumor was assessed. Complete responses were observed in 17/57 patients (30%) in the two studies, demonstrating activity against established cancer. These results are shown below:
After responses, the durability of remission is the most important clinical parameter in patients undergoing adjuvant therapy after resection. In the two monotherapy trials, 12-month recurrence-free rates are 46% (26/57), and 24-month recurrence-free rates 33% (19/57). The results compare favorably with historical 24-month experience for treatment of BCG-unresponsive disease with investigational therapies of approximately 20% (ref. 1). Data from the phase 2 combination study showed recurrence free survival of 68% and 54% at 12 and 24 months.